| RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39.0 days
| 7 |
33.73 |
uV |
9.28 |
24.55 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
MPEP |
a-wave amplitude ERG |
108540 |
3123 |
| RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39.0 days
| 7 |
192.0 |
uV |
14.42 |
38.15 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
pbs |
a wave amplitude ERG |
108545 |
3123 |
| RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39.0 days
| 7 |
233.29 |
uV |
18.61 |
49.24 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
pbs |
a wave amplitude ERG |
108546 |
3123 |
| RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39.0 days
| 7 |
11.45 |
uV |
3.56 |
9.42 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
MPEP |
a-wave amplitude ERG |
108537 |
3123 |
| RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-2.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39.0 days
| 7 |
83.4 |
uV |
14.8 |
39.16 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
pbs |
a wave amplitude ERG |
108543 |
3123 |
| RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39.0 days
| 7 |
145.24 |
uV |
12.56 |
33.23 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
pbs |
a wave amplitude ERG |
108544 |
3123 |
| RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39.0 days
| 7 |
5.86 |
uV |
0.76 |
2.01 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
MPEP |
a-wave amplitude ERG |
108536 |
3123 |
| RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-4.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39.0 days
| 7 |
7.44 |
uV |
1.43 |
3.78 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
pbs |
a wave amplitude ERG |
108542 |
3123 |
| RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.5 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39.0 days
| 7 |
18.53 |
uV |
4.77 |
12.63 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
MPEP |
a-wave amplitude ERG |
108538 |
3123 |
| RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39.0 days
| 7 |
36.49 |
uV |
10.37 |
27.44 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
MPEP |
a-wave amplitude ERG |
108541 |
3123 |
| RCS-p+/LavRrrc |
scotopic B wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (1 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39.0 days
| 7 |
251.29 |
uV |
19.14 |
50.64 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
pbs |
a wave amplitude ERG |
108547 |
3123 |
| RCS-p+/LavRrrc |
scotopic A wave amplitude of ERG waveform |
2-methyl-6-(phenylethynyl)pyridine (200 umol) then controlled exposure to darkness (for 12 hours) then visible light stimulus (-0.02 log(cd x m/s2)) |
Dai J, et al., Sci Rep. 2017 Jun 14;7(1):3546. doi: 10.1038/s41598-017-03702-z. |
rod electrophysiology trait |
both |
39.0 days
| 7 |
27.22 |
uV |
4.74 |
12.54 |
electroretinography |
cornea |
0.0 |
subretinal injection |
4 |
days |
MPEP |
a-wave amplitude ERG |
108539 |
3123 |